Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON44289
NL-OMON44289
Completed
Not Applicable

A phase 1 study to evaluate the absorption, metabolism and excretion of BCX7353 following administration of a single, oral dose of [14C]-radiolabeled BCX7353 to healthy male subjects. - BCX7353 ADME Study

BioCryst Pharmaceuticals, Inc.0 sites7 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
BioCryst Pharmaceuticals, Inc.
Enrollment
7
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •healthy male subjects
  • •18 \- 65 years
  • •BMI 18\.0 \- 32\.0 kilograms/meter2
  • •non smoking

Exclusion Criteria

  • •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A phase 1 study to investigate the absorption, metabolism and excretion of [14C] AT1001 (migalastat hydrochloride) following a single oral administration in healthy volunteers.
NL-OMON35820Amicus Therapeutics, Inc.6
Completed
Not Applicable
A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjectsProstate cancer10036958
NL-OMON36117Millenium Pharmaceuticals6
Completed
Not Applicable
A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of Radiolabeled [14C] R924548 Following Single Oral Dose Administration in Healthy Male Subjectsimmune-mediated diseasesrheuma10003816
NL-OMON37118Rigel Pharmaceuticals, Inc6
Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of 14C-PTC299 Following Multiple Oral Dose Administrations in Healthy Volunteers
NL-OMON50826PTC Therapeutics, Inc.7
Completed
Not Applicable
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of PTC857 Following Oral Administration of a Single Dose of 14C-PTC857 at Steady-State Conditions in Healthy Male Volunteers.
NL-OMON51552PTC Therapeutics, Inc.8